Although anti-PD-1/anti-PD-L1 therapies have shown promising therapeutic effects against advanced NSCLC and locally advanced NSCLC, a large proportion of patients do not benefit from this treatment and selecting the right patient for therapy remains challenging8,9. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.